Supported JPIAMR projects and networks

JPIAMR has coordinated 13 transnational joint calls till date supporting 99 projects and 38 networks with over 1300 researchers by investing 125 million Euros within the six priority areas of the shared JPIAMR Strategic Research and Innovation Agenda (SRIA) with a One Health approach.

Explore the JPIAMR project database that presents interactive data on projects and networks supported under the various calls coordinated by the JPIAMR.

Click on the titles below for more information on the research activities and outcomes of the projects and the networks supported under the JPIAMR framework.

The JPIAMR six Priority topics are:

Diagnostics

Environment

Interventions

Surveillance

Therapeutics

Transmission

Filter among 137 projects

Reset filter

Investigating the mechanism of eradication of MDR bacteria by inorganic, organic, and protein-based nanoparticles (NPERDMDR)

Therapeutics

The increase in nosocomial infections is adding a substantial burden to the medical system as they result in extended periods of hospitalization. This increase is strongly associated with the emergence of antimicrobial-resistant bacterial strains over the last two decades.The widespread use of antibiotics has resulted in the evolution and spread of these resistant genetic determinants: multidrug resistant (MDR) and extremely drug resistant (XDR) bacteria. There is an urgent need to develop novel antimicrobial agents to be able to kill antibiotic-resistant bacteria.

New intervention strategy for tuberculosis: blocking multiple essential targets (noTBsec)

Therapeutics

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a disease responsible for almost 1.3 million deaths per year. In recent years, different classes of drug resistant M. tuberculosis strains have emerged, making the discovery of novel anti-TB drugs a major global priority. This awareness has resulted in several new initiatives to find new (classes of) antimicrobial compounds. One of these initiatives is NM4TB, a consortium containing two noTBsec members, which discovered the benzothiazinones as promising new antimycobacterial compounds. A major disadvantage of most existing and new TB compounds is that they target a single molecule, which significantly increases the chance that resistant strains will emerge.

Repotentiating Beta Lactam antibiotics (REBEL)

Therapeutics

The most common form of resistance to ß-lactam antibiotics is the expression of ß-lactamase enzymes. These bacterial enzymes are capable of inactivating ß-lactam drugs by hydrolyzing their ßlactam ring, rendering them ineffective. Co-administration of a ß-lactam antibiotic with a ßlactamase inhibitor is a recognized strategy to circumvent this type of bacterial resistance, yet the number of compounds that have actually made it to clinical application so far is extremely limited.

Structure-guided design of pan inhibitors of metallo-p-lactamases (DesInMBL)

Therapeutics

The fight against infectious diseases is one of the greatest public health challenges, especially with the emergence of pan-drug resistant carbapenemase-producing Gram-negative bacteria. In particular, the pandemic NDM-1 and other plasmid-borne metallo-ß-lactamases (MBLs) disseminating worldwide in Gram-negative organisms threaten to take medicine back to the pre-antibiotic era as the treatment options remaining for infections caused by these “superbugs” are very limited.

Non-conventional approaches for peptidoglycan cross-linking inhibition (NAPCLI)

Therapeutics

Peptidoglycan (PG) is an attractive and validated target for antibacterial drug development for two main reasons. First, it is an essential and unique bacterial cell wall polymer with no counterpart in human cells, minimizing the risk of drug toxicity. Second, the essential PG synthases are exposed at the outer surface of the cytoplasmic membrane, making them highly accessible for antibiotic inhibition.

Capturing the natural antibiotic’ome: Developing Nature’s EVOIved AntiBIOTIC Collective (EVOBIOTIC)

Therapeutics

Naturally evolved antibiotics are our primary mode of treating drug-resistant pathogens. Although individual antibiotics do succumb to resistance via pressures they place on organisms, the producers of these agents innovate through modular antibiotic drug (bio)synthesis programs to naturally thwart drug resistance mechanisms.

Global Antimicrobial resistance Platform for ONE Burden Estimates (GAP-ONE)

Environment

Surveillance

Many global and international institutions and organisations acknowledge the cost of antimicrobial resistance (AMR). Even so, current figures fail to capture the full health and economic burden caused by AMR.